MPL
Basic information
Region (hg38): 1:43337818-43354466
Links
Phenotypes
GenCC
Source:
- thrombocythemia 2 (Strong), mode of inheritance: AD
- thrombocythemia 2 (Definitive), mode of inheritance: AD
- congenital amegakaryocytic thrombocytopenia (Supportive), mode of inheritance: AR
- familial thrombocytosis (Supportive), mode of inheritance: AD
- hereditary isolated aplastic anemia (Supportive), mode of inheritance: AD
- thrombocythemia 2 (Strong), mode of inheritance: AD
- congenital amegakaryocytic thrombocytopenia (Definitive), mode of inheritance: AR
- congenital amegakaryocytic thrombocytopenia (Strong), mode of inheritance: AR
- thrombocythemia 2 (Definitive), mode of inheritance: AD
- congenital amegakaryocytic thrombocytopenia 1 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Thrombocythemia 2; Amegakaryocytic thrombocytopenia, congenital, 1 | AD/AR | Hematologic; Oncologic | For Thrombocythemia 2, manifestations may include thrombotic/hemorrhagic episodes, as well as leukemic transformation, and surveillance and prompt treatment may be beneficial; For Amegakaryocytic thrombocytopenia, individuals may have findings such as severe bleeding complications, and platelet transfusion can be beneficial; Effective SCT has been described | Hematologic; Oncologic | 9029014; 10077649; 11133753; 14764528; 15269348; 16351641; 17054430 |
ClinVar
This is a list of variants' phenotypes submitted to
- Essential thrombocythemia;Congenital amegakaryocytic thrombocytopenia (51 variants)
- Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia (27 variants)
- Congenital amegakaryocytic thrombocytopenia (17 variants)
- not provided (7 variants)
- not specified (5 variants)
- Congenital amegakaryocytic thrombocytopenia 1 (3 variants)
- Primary myelofibrosis (2 variants)
- Thrombocythemia 2;Congenital amegakaryocytic thrombocytopenia;Primary myelofibrosis (2 variants)
- Thrombocytopenia (1 variants)
- MPL-related disorder (1 variants)
- Congenital amegakaryocytic thrombocytopenia;Thrombocythemia 2;Primary myelofibrosis (1 variants)
- Thrombocythemia 2 (1 variants)
- Thrombocythemia 1 (1 variants)
- Congenital amegakaryocytic thrombocytopenia;Primary myelofibrosis;Thrombocythemia 2 (1 variants)
- Myeloproliferative neoplasm (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MPL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 206 | 208 | ||||
missense | 14 | 139 | 167 | |||
nonsense | 34 | 23 | 58 | |||
start loss | 0 | |||||
frameshift | 41 | 17 | 59 | |||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 19 | 23 | ||||
splice region | 3 | 35 | 2 | 40 | ||
non coding | 25 | 106 | 138 | |||
Total | 85 | 73 | 170 | 319 | 8 |
Highest pathogenic variant AF is 0.000263
Variants in MPL
This is a list of pathogenic ClinVar variants found in the MPL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-43337836-A-C | Congenital amegakaryocytic thrombocytopenia | Uncertain significance (Jan 12, 2018) | ||
1-43337854-C-T | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Jan 09, 2024) | ||
1-43337857-C-G | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Oct 13, 2022) | ||
1-43337858-T-C | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Uncertain significance (Sep 11, 2023) | ||
1-43337859-G-A | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Pathogenic (Nov 02, 2023) | ||
1-43337860-G-A | Congenital amegakaryocytic thrombocytopenia | Uncertain significance (Aug 16, 2021) | ||
1-43337870-A-G | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Uncertain significance (Jan 26, 2022) | ||
1-43337875-C-T | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Nov 20, 2023) | ||
1-43337890-C-T | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Aug 18, 2021) | ||
1-43337893-G-GTATAAGAGACA | Congenital amegakaryocytic thrombocytopenia | Likely pathogenic (Jan 24, 2022) | ||
1-43337897-C-T | Congenital amegakaryocytic thrombocytopenia | Uncertain significance (Jan 12, 2018) | ||
1-43337899-T-G | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Dec 16, 2020) | ||
1-43337900-CA-C | Congenital amegakaryocytic thrombocytopenia | Likely pathogenic (Jan 28, 2022) | ||
1-43337905-C-A | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia • Inborn genetic diseases | Conflicting classifications of pathogenicity (Nov 24, 2023) | ||
1-43337917-C-A | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Oct 04, 2023) | ||
1-43337928-G-A | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely pathogenic (Dec 26, 2022) | ||
1-43337928-G-T | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely pathogenic (Dec 14, 2020) | ||
1-43337929-T-A | not specified • Congenital amegakaryocytic thrombocytopenia • Congenital amegakaryocytic thrombocytopenia;Primary myelofibrosis;Thrombocythemia 2 • MPL-related disorder • Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia • Thrombocytopenia • Primary myelofibrosis | Pathogenic/Likely pathogenic (Jan 29, 2024) | ||
1-43337934-T-C | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Feb 05, 2020) | ||
1-43337935-G-C | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Jun 11, 2022) | ||
1-43337936-C-G | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Feb 22, 2023) | ||
1-43337936-C-T | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Dec 12, 2023) | ||
1-43337937-A-C | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Nov 04, 2023) | ||
1-43337942-G-A | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Jun 28, 2023) | ||
1-43337942-G-C | Congenital amegakaryocytic thrombocytopenia;Essential thrombocythemia | Likely benign (Aug 08, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MPL | protein_coding | protein_coding | ENST00000372470 | 12 | 14966 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.07e-9 | 0.997 | 125546 | 0 | 202 | 125748 | 0.000804 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.395 | 311 | 331 | 0.939 | 0.0000181 | 4043 |
Missense in Polyphen | 83 | 88.638 | 0.93639 | 1120 | ||
Synonymous | 2.42 | 101 | 137 | 0.737 | 0.00000719 | 1313 |
Loss of Function | 2.72 | 20 | 38.1 | 0.525 | 0.00000224 | 362 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000543 | 0.000543 |
Ashkenazi Jewish | 0.00834 | 0.00817 |
East Asian | 0.000598 | 0.000598 |
Finnish | 0.0000924 | 0.0000924 |
European (Non-Finnish) | 0.000621 | 0.000615 |
Middle Eastern | 0.000598 | 0.000598 |
South Asian | 0.000621 | 0.000621 |
Other | 0.000999 | 0.000978 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for thrombopoietin that acts as a primary regulator of megakaryopoiesis and platelet production. May represent a regulatory molecule specific for TPO-R-dependent immune responses. {ECO:0000250|UniProtKB:Q08351}.;
- Disease
- DISEASE: Congenital amegakaryocytic thrombocytopenia (CAMT) [MIM:604498]: Disease characterized by isolated thrombocytopenia and megakaryocytopenia with no physical anomalies. {ECO:0000269|PubMed:16470591, ECO:0000269|PubMed:25538044}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Thrombocythemia 2 (THCYT2) [MIM:601977]: A myeloproliferative disorder characterized by excessive platelet production, resulting in increased numbers of circulating platelets. It can be associated with spontaneous hemorrhages and thrombotic episodes. {ECO:0000269|PubMed:14764528, ECO:0000269|PubMed:19483125, ECO:0000269|PubMed:23441089, ECO:0000269|PubMed:25538044}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myelofibrosis with myeloid metaplasia (MMM) [MIM:254450]: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly. {ECO:0000269|PubMed:16834459, ECO:0000269|PubMed:16868251}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Jak-STAT signaling pathway - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);JAK-STAT-Core;JAK STAT MolecularVariation 1;Platelet Aggregation (Plug Formation);Platelet activation, signaling and aggregation;tpo signaling pathway;JAK STAT MolecularVariation 2;Hemostasis;JAK STAT pathway and regulation;TPO signaling
(Consensus)
Recessive Scores
- pRec
- 0.282
Intolerance Scores
- loftool
- 0.343
- rvis_EVS
- -0.53
- rvis_percentile_EVS
- 20.82
Haploinsufficiency Scores
- pHI
- 0.710
- hipred
- Y
- hipred_score
- 0.598
- ghis
- 0.466
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.932
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mpl
- Phenotype
- growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; embryo phenotype; immune system phenotype;
Zebrafish Information Network
- Gene name
- mpl
- Affected structure
- thromboblast
- Phenotype tag
- abnormal
- Phenotype quality
- decreased occurrence
Gene ontology
- Biological process
- neutrophil homeostasis;cell surface receptor signaling pathway;cell population proliferation;monocyte homeostasis;thrombopoietin-mediated signaling pathway;positive regulation of lymphocyte proliferation;platelet aggregation;cellular response to hypoxia;positive regulation of platelet formation;eosinophil homeostasis;basophil homeostasis
- Cellular component
- Golgi apparatus;plasma membrane;integral component of plasma membrane;cell surface;neuron projection;neuronal cell body
- Molecular function
- transmembrane signaling receptor activity;protein binding;thrombopoietin receptor activity